Mary Keir - Senior Scientist, Biomarker Discovery OMNI

Mary Keir

Senior Scientist, Biomarker Discovery OMNI

"Working at Genentech gives us a unique opportunity to apply our understanding of biology gained from simpler systems and observational studies to challenging clinical problems."
10
Years at Genentech
13
Publications
6
Awards & Honors

My career path has grown out of my interest in understanding human disease. I received my Ph.D. in Biomedical Sciences at the University of California, San Francisco, where my thesis work focused on innate responses to HIV infection in the human thymus and used patient data to inform studies in simpler model systems. After receiving my Ph.D., I undertook postdoctoral training at Harvard Medical School with the goal of mastering genetic deletion approaches to understanding disease biology. While at Harvard, I studied the role of PD-1:PD-L1 interactions in T cell tolerance and autoimmunity in mouse models.

I returned to patient-based disease biology research when I joined the Biomarker Discovery group at Genentech and I have found it extremely rewarding (and challenging!) to apply my training to pick apart human disease biology. In our group, we lead biomarker identification and work within clinical studies to evaluate disease biology. My lab has worked on biomarker discovery across several diseases at Genentech; currently, our primary focus is on inflammatory bowel disease (IBD). Our goal is to discover and develop predictive biomarkers of patient subgroups in IBD as well as develop prognostic biomarkers of disease.

Featured Publication

αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis.

J Crohns Colitis. 2017 May 1;11(5):610-620.

Lamb CA, Mansfield JC, Tew GW, Gibbons D, Long AK, Irving P, Diehl L, Eastham-Anderson J, Price MB, O'Boyle G, Jones DEJ, O'Byrne S, Hayday A, Keir ME, Egen JG, Kirby JA.